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Abstract
Background: Wegener's Granulomatosis and Microscopic Polyangiitis are life-threatening systemic necrotizing
vasculitides of unknown aetiology. The appearance of circulating antibodies to neutrophil cytoplasmic antigens
(ANCA) is strongly associated with the development of the disease. A link between infection and disease has long
been suspected, and the appearance of ANCA antibodies has been reported following bacterial and viral
infections. The depletion of circulating B cells with monoclonal antibody therapy can induce remission, and this
observation suggests a pathogenic role for B cells in this disease. As bacterial DNA is known to induce B cell
proliferation and antibody production via TLR-9 stimulation, we have explored the possibility that unmethylated
CpG oligodeoxynucleotide, as found in bacterial and viral DNA, may play a role in stimulating circulating
autoreactive B cells to produce ANCA in patients with vasculitis.
Results: We have confirmed that unmethylated CpG oligonucleotide is a potent stimulator of antibody
production by PBMC in vitro. The stimulation of PBMC with CpG oligonucleutides resulted in the production of
similar amounts of IgG in both ANCA+ patients and normal controls. In spite of this, PR3 ANCA+ patients
synthesised significantly higher amount of IgG ANCA than normal controls. In MPO ANCA+ patients, there was
a tendency for patients to produce higher amount of ANCA than controls, however, the difference did not reach
significance. Furthermore, we were able to detect circulating MPO-reactive B cells by ELISpot assay from the
peripheral blood of 2 MPO+ ANCA vasculitis patients. Together, this indicates that circulating anti-neutrophil
autoreactive B cells are present in ANCA+ vasculitis patients, and they are capable of producing antibodies in
response to CpG stimulation. Of note, CpG also induced the production of the relevant autoantibodies in patients
with other types of autoimmune diseases.
Conclusion: Circulating ANCA autoreactive B cells are present in patients with ANCA+ vasculitis. The
production of ANCA from these cells in response to unmethylated CpG stimulation lead us to propose that
stimulation of these cells by immunostimulatory DNA sequences such as CpG oligodeoxynucleotide during
infection may provide a link between infection and ANCA associated vasculitis. This phenomenon may also apply
to other antibody mediated autoimmune diseases.
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The presence of circulating anti-neutrophil cytoplasmic
antibodies (ANCA) has been found to be strongly associ-
ated with the development of Wegener's Granulomatosis
and Microscopic Polyangiitis [1,2], commonly known as
ANCA associated vasculitis. These conditions are charac-
terised by systemic necrotising vasculitis, arthralgia, myal-
gia, inflammation of the upper and lower respiratory
tracts, and acute necrotising glomerulonephritis. Protein-
ase-3 (PR3) and myeloperoxidase (MPO) are the most
common neutrophil antigens targeted [3,4]. Notably,
ANCA specificity in these patients is directed against
either PR3 or MPO but seldom both. Infrequently, other
neutrophil-derived antigens such as elastase and cathep-
sin G can instead be targeted.
Although the pathogenic role of ANCA remains contro-
versial, there is increasing evidence that B cells and ANCA
autoantibodies are important. For example, the depletion
of CD20+ peripheral B cells with Rituximab can bring
about remission in patients with refractory ANCA+ vascu-
litis [5]. In many though not all patients, the titre of serum
ANCA mirrors disease activity [6,7]. Furthermore, plasma
exchange may have a therapeutic role [8]. An animal
model of ANCA associated vasculitis has been attempted
by raising antibodies to MPO in MPO-/- knockout mice
[9]. These antibodies which had been raised against MPO
as a neo-antigen caused necrotizing glomerulonephritis
when injected into wild type mice.
The strongest evidence for ANCA in the pathogenesis of
vasculitis resides in in vitro experiments [10,11]. They
demonstrated binding of ANCA to cytokine-primed neu-
trophils resulting in neutrophil activation and degranula-
tion, with the consequent release of reactive oxygen
species and inflammatory cytokines, and subsequent cel-
lular damage to neighbouring endothelial cells.
Another potential role of circulating IgG autoantibodies
in the pathogenesis of antibody-mediated autoimmune
disease may be to assist B cells and dendritic cells in the
capture of autoantigens and subsequent presentation to T
cells, thus contributing to the development and mainte-
nance of autoantibody production [12,13].
In the case of ANCA associated vasculitis, infection has
been suspected to play an important role in development
of the disease. Friedrich Wegener first suggested the possi-
ble association of infection with Wegener's Granulomato-
sis while describing the disease [14,15]. Extensive studies
have been carried out demonstrating the association of
carriage of staphylococcus aureus in the nasal passages and
Wegener's Granulomatosis [16]. This finding may be rele-
vant to the manifestation of clinical pathology within the
sinuses and the upper respiratory tract. In addition, the
appearance of ANCA has been regularly reported in asso-
ciation with other infections such as bacterial endocarditis
(anti-MPO by ELISA [17], and dual anti-MPO and PR3 by
ELISA [18]), leprosy (determined by immunofluorescence
only) [19], tuberculosis (mainly anti-PR3) [20], hepatitis
C (anti-bactericidal/permeability increasing protein or
Cathepsin G) [21], and parvovirus B19 (anti-MPO or
PR3) [22].
Pendergraft and colleagues have reported that mice
injected with antisense DNA-encoded PR3 generated anti-
bodies that in turn stimulated anti-idiotypic antibodies,
which recognised sense DNA-encoded PR3. Based on this
phenomenon, they proposed that peptides derived from
microbial organisms, which shared sequence homology
with antisense DNA-encoded PR3, may serve as potential
antigens to initiate autoimmunity [23].
In view of 1) the possible aetiological connection between
infection and this disease, 2) the fact that Toll-like recep-
tors (TLRs) play a critical role in the innate recognition of
infectious pathogens by the immune system [24,25] 3) B
cells are known to respond to viral and bacteria derived
TLR-ligands such as CpG oligodeoxynucleotides, and 4)
experimental evidence in murine animal models showing
that TLRs are important to the development of several
autoimmune disorders (reviewed in [26]), we wanted to
examine the effect of TLR stimulation on the production
of ANCA in vasculitis patients.
In this study, we focus on the effect of TLR stimulation, in
particular the stimulation of PBMCs by the TLR-9 specific
ligand single-stranded DNA with CpG motifs, CpG oligo-
deoxynucleotide (CpG) as found in bacteria and viruses,
to see if this agent might stimulate in vitro production of
IgG ANCA from patients with ANCA+ vasculitis. CpG
sequences of bacterial and viral origin are hypomethyl-
ated in contrast to mammalian DNA which is predomi-
nantly methylated. It is thought that this difference in
methylation status is one of the ways by which humans
avoid responding to self-DNA [26]. We chose to concen-
trate on TLR-9 because TLR-9 is expressed mainly by B
cells and plasmacytoid dendritic cells in humans [27] and,
stimulation of TLR-9 by CpG is known to induce B cell
proliferation and antibody production in vitro and in vivo
[28].
Results
CpG-B induces PBMCs to produce ANCA in vasculitis 
patients in vitro
PBMCs were isolated from 10 patients with biopsy-proven
ANCA+ vasculitis, each paired to a normal control indi-
vidual, and cultured in the presence of CpG-B and IL-2.
Patient clinical details are shown in Table 1. Notably, all
but one of these patients were not receiving immunosup-Page 2 of 9
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supernatants were harvested after 12 days of culture, and
concentration of IgG measured by ELISA as well as their
reactivity against PR3 or MPO (Fig. 1). The supernatants
from PR3+ and MPO+ ANCA patients were tested for reac-
tivity against PR3 or MPO antigen respectively. We found
that CpG B at 3.2 mg μg mL-1 to be a strong stimulant of
IgG production in vitro. The amount of IgG detected in the
supernatants were similar in both patient and control
groups, with a concentration of 5.5 ± 2.2 and 4.1 ± 1.2 μg
mL-1 respectively (Fig. 1A). The reactivity against PR3 and
MPO antigens in the patients' supernatants were consist-
ently greater than those observed in normal controls. In
PR3+ ANCA patients, this difference achieved significant
levels (P = 0.0082) (Fig. 1B). In MPO+ patients the differ-
ence was not significant (P = 0.072) although their super-
natants showed a clear tendency towards higher reactivity
(Fig. 1C). There was no correlation between serum ANCA
titre and the amount of ANCA produced in vitro (r2 =
0.172) (Fig. 1D). In addition to CpG-B, PBMCs from 5
different pairs were also stimulated with LPS, pokeweed
mitogen (PWM) or inactivated staphylococcus aureus (Fig.
CpG-B induces ANCA production from vasculitis patients in vitroFigure 1
CpG-B induces ANCA production from vasculitis patients in vitro. PBMCs isolated from patients with active ANCA 
associated vasculitis, 5 PR3+ and 5 MPO+ ANCA patients, were cultured with CpG-B and IL-2. Each patient assay was paired 
with a healthy control. After 12 days of culture, supernatants were harvested. IgG concentration and supernatant reactivity to 
either PR3 or MPO was measured by ELISA. The amount of IgG detected in the supernatants was of 5.5 ± 2.2 μg mL-1 in the 
patients compared to 4.1 ± 1.2 μg mL-1 in the control group (A). Figure B shows the reactivity of the supernatants from PR3+ 
ANCA patients towards PR3 antigen. The difference against control individuals was highly significant (P = 0.0082). Figure C 
shows the reactivity of the supernatants from MPO+ ANCA patients towards MPO antigen. The difference was not significant 
(P = 0.072) although their supernatants showed a clear tendency towards higher reactivity compared to controls. There was no 
correlation between patients' serum ANCA titre at the time of the assay and their in vitro production of ANCA in response to 
CpG-B as shown in D (r2 = 0.172).Page 3 of 9
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nificantly lower compared to CpG-B and we were not able
to detect ANCA in these conditions. The inactivated sta-
phylococcus aureus used in these experiments had been
formalin fixed. In this form, they are unlikely to provide
freely available unmethylated CpG, even though they
should contain unmethylated CpG within.
Detection of peripheral blood circulating B cells capable of 
producing ANCA in response to CpG-B
The production of ANCA autoantibodies by PBMCs in
ANCA+ vasculitis patients suggested the presence of circu-
lating ANCA autoreactive B cells in these patients. In order
to test this possibility, we attempted to detect peripheral
blood circulating B cells that are capable of producing
ANCA by ELISpot. PBMCs isolated from a MPO+ ANCA
patient who had had a relapse of vasculitis disease
(patient no.8 in Table 1) were cultured with CpG-B and
IL-2 for 5 days. Cells were then transferred into wells pre-
viously coated with either myeloperoxidase antigen or
control antigen, and cultured overnight. Antibody pro-
ducing cells that had produced IgG antibody against these
antigens were detected by an anti-human IgG antibody.
The ELISpot assay shows the presence of MPO-reactive B
cells within the PBMC population of the MPO+ ANCA
vasculitis patients but not of the control individuals (Fig.
3). Together, the above data indicate that ANCA+ vasculi-
tis patients have in their peripheral circulation B cells
which are capable of producing ANCA in response to CpG
stimulation.
CpG-B also induced production of the relevant IgG 
autoantibodies in patients with other autoimmune 
diseases in vitro
To test if the CpG-B effect of inducing autoantibody pro-
duction may be seen in other autoimmune diseases
besides ANCA+ vasculitis, the same experimental proce-
dure was performed in patients presenting with other
types of autoimmune diseases, namely autoimmune thy-
roiditis and anti-phosphoslipid antibody syndrome.
These patients were similar to most of our ANCA+ vascu-
litis patients in that they were not taking immunosuppres-
sive medications at the time of study. We observed that
stimulation of PBMCs with CpG-B and IL-2 led to the pro-
duction of IgG anti-thyroperoxidase and anti-cardiolipin
antibodies from the majority of patients with thyroiditis
(3 out of 4 patients) and anti-phosphoslipid antibody
syndrome respectively (2 out of 3 patients) (Fig. 4). These
patients did not produce ANCA after CpG-B stimulation
in vitro (data not shown).
Discussion
It is known that low affinity autoreactive B cells are part of
our normal immune repertoire [29], and several studies
have demonstrated the presence of circulating autoreac-
tive B cells in autoimmune diseases such as autoimmune
thyroiditis [30] and systemic lupus erythematosus (SLE)
[31]. In human SLE, Boumpas and colleagues have
recently reported the finding of an increased number of
TLR-9-expressing memory B cells and plasma cells in
patients with active disease [32]. This is highly relevant to
the report by Marshak-Rothstein and colleagues who had
shown that co-engagement of BCR and TLR-9 by com-
plexes of anti-DNA antibody and DNA may provide a
mechanism for stimulation of autoreactive B cells in lupus
[33]. This demonstration becomes even more relevant
given that patients with SLE have impaired DNA methyl-
ation [34,35]. It may also provide a tangible explanation
for the beneficial effect of agents like hydroxychloroquine
that inhibit TLR-9 signaling by disturbing endosomal
acidification.
In vitro ANCA production is induced by CpG-B but not by other B cell stimulantsFigu e 2
In vitro ANCA production is induced by CpG-B but 
not by other B cell stimulants. In addition to CpG-B + 
IL2, PBMCs from 5 different pairs were also stimulated with 
either IL2 alone, LPS + IL2, pokeweed mitogen (PWM) + IL2, 
or inactivated staphylococcus aureus + IL2. A representative 
set of results is shown from a PR3+ ANCA patient (A) and a 
MPO+ ANCA patient (B).Page 4 of 9
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lating ANCA autoreactive B cells in patients with ANCA+
vasculitis. In addition, we demonstrate that these cells are
capable of producing ANCA autoantibodies in response
to molecular ligands derived from bacteria and viruses
such as CpG ODN. These findings provide experimental
support for a link between infection and development of
ANCA autoantibody.
Lanzavecchia and colleagues have reported that memory
B cells proliferated and differentiated into antibody-
secreting cells in response to CpG even in the absence of
specific antigen stimulation [36]. They showed that CpG
led to polyclonal activation of B cells against a range of
vaccine and pathogen derived antigens, and they pro-
posed that this microbial stimulus provided a mechanism
whereby serological memory of human memory B cells is
maintained. In the case of ANCA associated vasculitis, we
propose a parallel mechanism, whereby microbial CpG
ODN may contribute to the maintenance of ANCA auto-
reactive memory B cells and ANCA autoantibody produc-
tion in patients with ANCA associated vasculitis.
Our findings that CpG-B stimulates the production of the
relevant autoantibodies in vitro in patients with ANCA
associated vasculitis, autoimmune thyroiditis and anti-
phospholipid antibody syndrome suggest that this mech-
anism may also apply to the maintenance of autoreactive
memory B cells in other antibody mediated autoimmune
diseases.
Besides being the target of ANCA autoantibodies, neu-
trophils may also play an accessory role to drive the
expansion of ANCA reactive B cells. Recently, Brinkmann
and colleagues showed that activated human neutrophils
release DNA to form neutrophil extracellular traps (NETs)
[37,38]. The function of NETs is to ensnare and inactivate
bacteria in defense against invading infection. Interest-
ingly, the DNA in NETs is integrated with neutrophil anti-
gens such as myeloperoxidase, elastase and cathepsin G.
Given the highly cationic nature of these molecules (for
example, the pI values of PR3, MPO, elastase, cathepsin G
are 7.79, 9.22, 9.89 and 11.3 respectively), there is a theo-
retical possibility that neutrophil DNA from NETs or CpG
sequences derived from bacteria caught in NETs may pref-
erentially stimulate ANCA reactive B cells by virtue of elec-
trostatic association between negatively-charged DNA and
these cationic neutrophil antigens. This may then result in
preferential expansion of ANCA reactive B cells. For
instance, highly cationic MPO may bind non-covalently
to negatively charged DNA containing hypomethylated
CpG sequences. After encounter with anti-MPO specific
autoreactive B cells, complexes of cationic MPO/CpG may
become internalised, and CpG-B may subsequently stim-
ulate TLR-9 within endosomes. This concept is supported
by a recent demonstration that internalization of BCR
antigen complex triggers the fusion of endocytic vesicles
with TLR-9 containing vesicles [39].
Another potential endogenous source of stimulatory CpG
could be latent viruses. Lund and colleagues have shown
that viral DNA from Herpes simplex virus can stimulate
murine TLR-9 [40]. Since the majority of individuals har-
bour herpes viruses and cytomegalovirus by adulthood,
and circulating viral DNA is detectable in serum, it would
be relevant to see if these viruses may provide a source of
hypomethylated CpG ODN to maintain autoreactive B
cells in patients with ANCA associated vasculitis.
Since the first description of circulating ANCA in patients
with Wegener's Granulomatosis, the vast majority of
research in this field has focused on the biological func-
tions of ANCA and whether they have a pathogenic role in
disease. In contrast, much less attention has been paid to
the role of ANCA specific circulating B cells in this disease.
Several studies have reported the successful use of Rituxi-
mab in patients with active disease [5,41]. The clinical
response to Rituximab is generally rapid. Interestingly, the
Table 1: Clinical and laboratory data of the patients at the time of study
Patient Number Age Gender ANCA Titre Clinical Status Treatment Organ Involvement
1 37 M PR3 60 U Remission Nil R, J
2 69 M PR3 34 U Newly Diagnosed Prednisolone 5 mg/day R, J
3 56 M PR3 >100 U Relapse Nil R, J, S, P
4 73 F PR3 >100 U Newly Diagnosed Nil R, L, E
5 50 M PR3 33 U Newly Diagnosed Nil L, E, J
6 63 M MPO >100 U Newly Diagnosed Nil R, L, C, J
7 77 M MPO 54 U Newly Diagnosed Nil R, L
8 67 M MPO 38 U Relapse Nil R, L
9 57 M MPO 47U Relapse Nil R, S, L
10 82 M MPO >100 U Newly Diagnosed Nil R, J
R = Renal, E = ENT, L = Lung, C = Cardiac, J = Joints, S = Skin, P = Peripheral NeuropathyPage 5 of 9
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culating B cells, but not immediately with the serum
ANCA titre, which may remain high for much longer
before decreasing. This observation makes us suspect that
ANCA-specific autoreactive B cells may possess additional
pathogenic roles in this disease above and beyond the
CpG-B also induced the production of relevant IgG autoanti-bodies in patients wi  other au oimmune diseasesFigure 4
CpG-B also induced the production of relevant IgG 
autoantibodies in patients with other autoimmune 
diseases. PBMCs from 4 patients with autoimmune thyroidi-
tis and 3 patients with anti-phospholipid antibody syndrome 
were cultured with CpG-B and IL-2. Each patient assay was 
paired with a healthy control. After 12 days of culture, super-
natants from autoimmune thyroiditis patients were tested by 
ELISA for IgG anti-thyroperoxidase (TPO) as shown in A. 
Supernatants from anti-phospholipid antibody syndrome 
patients were tested for IgG anti-cardiolipin antibodies 
(ACLA) as shown in B.
Detection of circulating B cells capable of producing ANCA in response to CpG-BFigure 3
Detection of circulating B cells capable of producing 
ANCA in response to CpG-B. PBMCs from 2 MPO+ 
ANCA vasculitis patients were cultured with CpG-B and IL-
2. These PBMCs had not undergone enrichment for B cells 
prior to culture. After 5 days culture, cells were transferred 
into ELISpot wells which had been coated with either mye-
loperoxidase (MPO) in duplicates or foetal calf serum (FCS) 
as a control antigen. After overnight culture, IgG antibody 
producing cells against these antigens were detected by anti-
human IgG conjugate. The total number of IgG producing B 
cells was measured by coating the wells with polyclonal anti-
human IgG. The results from a patient as shown in this figure 
are representative of results from 2 patients. Fig A shows 
ELIspot plate with total IgG producing cells in the first col-
umn followed by the detection of anti-MPO B cells in dupli-
cates in the middle columns and finally cells against the 
control antigen. The numbers of spots counted are depicted 
in Figure B. In spite of both patient and control having similar 
number of IgG producing cells, the number of anti-MPO B 
cells is higher in the MPO+ patient. This result coincide with 
those from a parallel experiment where PBMCs from this 
pair of individuals were cultured in the presence of CpG-B to 
measure their in vitro production of anti-MPO by ELISA as 
shown in (C).Page 6 of 9
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entation and cytokine production. Hence, it would be
equally worthwhile to investigate if exposure of B cells to
pathogen-derived CpG may stimulate these functions in
vasculitis.
Conclusion
Circulating ANCA autoreactive B cells are present in
patients with ANCA+ vasculitis. These cells are able to pro-
duce measurable amounts of ANCA in vitro. This response
seems to be limited to stimulation with CpG oligodeoxy-
nucleotide, as we could not detect ANCA in response to
other B cell stimulants such as LPS, pokeweed mitogen or
staphylococcus aureus. These findings lead us to propose
that stimulation of ANCA autoreactive B cells by immu-
nostimulatory DNA sequences such as CpG during infec-
tion may provide a link between infection and ANCA
associated vasculitis. This phenomenon may also operate
in other antibody mediated autoimmune diseases. Fur-
ther identification of the nature of immunostimulatory
oligodeoxynucleotides and ANCA autoreactive B cells in
patients may offer a greater understanding of the mecha-
nisms by which infection is associated with development
of this disease. The question of whether infection may
stimulate de novo production of ANCA in individuals
without vasculitis also warrants separate investigation.
This possibility will need to be addressed by examining a
large number of patients with different infections as the
propensity to produce ANCA in response to infection may
depend not only on the type of infection in question, but
also on the genetic predisposition of the infected individ-
ual.
Methods
PBMC separation and culture
25 mls of peripheral blood was obtained with consent
from ANCA+ vasculitis patients with biopsy proven dis-
ease. Consent was obtained in accordance to the ethical
standards specified by the Royal Adelaide Hospital
Human Ethics Committee. PBMC separation was per-
formed by density gradient over LymphoprepTM (Axis-
Shield, Oslo). After extensive washing, cells were resus-
pended in culture media (RPMI 1640 supplemented with
10% foetal calf serum, 2 mM L-glutamine, 100 U mL-1
penicillin, 100 mg mL-1 gentamicin) and adjusted to a
final concentration of 1 × 106 cells mL-1. Each patient sam-
ple was prepared in parallel with a control sample
obtained at the same time from a healthy individual.
PBMCs were stimulated with 3.2 μg mL-1 of CpG-B ODN
2006 (5'-tcgtcgttttgtcgttttgtcgtt-3'), 3.2 ug mL-1 CpG-A
ODN 2216 (5'-ggGGGACGATCGTCgggggG-3'; small let-
ters, phosphorothioate linkage; bold, CpG dinucleotides;
capital letters, phosphodiester linkage 3' of the base;
Geneworks, Australia), IL-2 10 ng mL-1 (R&D Systems),
LPS 500 ng/ml (Sigma-Aldrich), pokeweed mitogen 3 μg
mL-1 (Sigma-Aldrich), inactivated staphylococcus aureus
Cowan's strain (Sigma-Aldrich) or media alone. All solu-
tions had been tested free of endotoxin. CpG was free of
endotoxin (< 0.1 EU/ml) while inactivated staphylococ-
cus aureus contained 1.53 EU/ml (LAL method, Charles
River PTS System). Cell culture supernatant was harvested
after 12 days of culture at 37°C, 5% CO2.
ELISA
Total IgG concentrations in cell culture supernatants were
measured by ELISA (Bethyl Laboratories) while ANCA
specificity was measured using ELISA to PR3, MPO, thy-
roperoxidase or cardiolipin (Orgentec, Germany). To
detect IgG ANCA in supernatant, samples were diluted 1:2
and incubated for 1 hr, followed by 1 hr with anti-human
IgG conjugated to horseradish peroxidase. Enzyme activ-
ity was detected using TMB substrate, stopped with hydro-
chloric acid and read at 450 nm.
ELISpot
PBMCs were cultured at 2 × 106 cells mL-1 in RPMI 1640
supplemented with 10% foetal calf serum, 2 mM L-
glutamine, 100 U mL-1 penicillin, 100 mg mL-1 gen-
tamicin, in the presence of CpG B 3.2 μg mL-1 and IL-2, at
37°C in 5% CO2 for 5 days. Twenty-four hours prior to
harvesting the cells, MultiScreen HTS 96 wells plate (Mil-
lipore, France) was activated with 15 μl of 70% methanol
for two minutes and washed once with endotoxin-free
PBS. The wells were coated with 100 μl of either goat anti-
human IgG (Jackson ImmunoResearch), 20 μg mL-1 of
purified myeloperoxidase (Calbiochem, Germany) or
10% foetal calf serum, all diluted in carbonate/bicarbo-
nate buffer 0.15 M, pH 9.6. The plates were washed and
blocked with 100 μl of complete media and incubated for
90 min at 37°C. Meanwhile, cells were collected, washed
4× in complete media and adjusted to a final cell density
of 2.5 × 106 μL mL-1. 100 μL well-1 of the cell suspension
was placed in the ELISpot plate in duplicate and cultured
for further 12 hrs. Plates were washed with PBS and incu-
bated with 100 μl of goat anti-human IgG conjugated to
alkaline phosphatase (Sigma, Germany) diluted 1:3000,
at 4°C overnight. Plates were washed and developed by
adding 100 μL well-1 of BCIP/NBT Plus (Mabtech,
Sweeden). The reaction was stopped at 8 min by rinsing
the plate with running water. Plates were read by AID
plate reader (Autoimmune Diagnostica, Germany).
Statistics analysis
Data are presented as means ± standard error of the mean
(SEM), and the significant differences were determined
using Student's t test using GraphPad Prism Software [42].
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